Compare YieldMax AI & Tech Portfolio Option Income ETF (GPTY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AI & Tech Portfolio Option Income ETF vs GeneDx Holdings Corp — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $41.3, while GeneDx Holdings Corp trades at $61.39 (market cap $1.96B). The key difference: YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| GPTY | WGS | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $50.52 | $167.51 |
52-Week Low | $34.73 | $34.51 |
Market Cap | — | $1.96B |
Enterprise Value | — | $1.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPTY trades at $41.41, down 3.97% on the day, with technical indicators showing a neutral to bearish bias. The ETF maintains a consistent weekly dividend distribution strategy, with recent payouts ranging from $0.30 to $0.38. Support and resistance levels cluster tightly around $43-$46, indicating potential for near-term consolidation. Recent news highlights focus on its option-income strategy and comparisons to peers like ULTY.
The outlook balances high yield potential against market volatility risks. Investment appeal centers on AI/tech exposure coupled with income generation, but reliance on semiconductor momentum and option premiums introduces volatility. Key risks include NAV erosion from the covered call strategy and sector concentration, requiring careful risk assessment for income-focused investors.
WGS trades at $62.73, up 0.48% on the day, amid a bearish technical signal and negative earnings momentum. The stock faces significant headwinds from a class action lawsuit alleging securities fraud tied to a 49% stock decline, while fundamentals show a net loss of $21.02 million in 2025 and deteriorating profitability into 2026. Analyst consensus remains bullish with a $75.40 price target, but recent news flow is overwhelmingly negative.
The outlook is clouded by legal risks and weak financial performance, though analyst optimism suggests potential recovery if the company can stabilize operations. Key risks include litigation outcomes, execution on profitability, and market sentiment shifts. The stock's trajectory hinges on resolving legal challenges and demonstrating sustainable earnings improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
